IGF1 and acromegaly: Of interest, some patients had lost biochemical response between screening and the baseline visit in both trials: 12% of patients in CH-ACM-01 and 11% of patients in CHIASMA OPTIMAL no longer had IGF-I levels below the screening cutoff, suggesting variability in IGF-I levels in patients with biochemically controlled acromegaly (Table 2).